Auto Owners Insurance Co Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Auto Owners Insurance Co increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 57,845.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,427,896 shares of the medical research company’s stock after acquiring an additional 2,423,706 shares during the quarter. Thermo Fisher Scientific makes up about 0.3% of Auto Owners Insurance Co’s portfolio, making the stock its 29th biggest holding. Auto Owners Insurance Co’s holdings in Thermo Fisher Scientific were worth $1,406,844,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. High Note Wealth LLC raised its position in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $28,000. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.3%

Shares of TMO stock opened at $465.98 on Friday. The company has a 50-day moving average of $476.59 and a two-hundred day moving average of $523.32. The firm has a market cap of $173.17 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the company posted $5.15 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.